Caroline Seymour

Articles

Niraparib and abiraterone combo significantly delays mCRPC progression

February 18, 2022

Findings from the phase 3 MAGNITUDE trial showed that adding niraparib to abiraterone acetate significantly extended radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.